The Fortune 500 pharma giant will sequence the exomes of 10 million people, with the goal of developing new therapies and ...

After Regeneron Chief Scientific Officer George Yancopoulos, M.D., Ph.D., spent more than 25 minutes waxing about the company ...

Regeneron Pharmaceuticals Inc (REGN) stock saw a decline, ending the day at $681.58 which represents a decrease of $-11.65 or -1.68% from the prior close of $693.23. The stock opened at $705.34 and ...

Regeneron Pharmaceuticals Inc.'s executives and board members overstated its key eye treatment’s average selling price, ...

Regeneron Pharmaceuticals Inc. closed 42.77% short of its 52-week high of $1,211.20, which the company achieved on August ...

SAN DIEGO, CA / ACCESSWIRE / January 15, 2025 / Robbins LLP reminds investors that a class action was filed on behalf of all ...

Regeneron Pharmaceuticals Inc. closed 41.92% below its 52-week high of $1,211.20, which the company reached on August 27th.

Medical data research company Truveta said on Monday that Regeneron Pharmaceuticals, Illumina and 17 U.S. health systems will ...

UBS downgraded Regeneron (REGN) to Neutral from Buy with a price target of $738, down from $1,130. The firm believes there is a disconnect ...

Illumina and Regeneron are taking stakes in health data company Truveta to help fund research that may dwarf the efforts of ...

Regeneron shares have been in a bearish trend since August, losing over one third of their value. Read why I am initiating ...

North Shore High School students Kaitlin Ho and Eli Weseley-Jones were named among the top 300 scholars in the 2025 Regeneron ...